DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- 2.6k Downloads
Lipid profile is an important determinant of cardiovascular risk in type 2 diabetic patients. Available glucose-lowering agents can affect lipid levels. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to reduce total cholesterol, but results are inconsistent across trials. The present metaanalysis was designed to assess the effect of DPP-4 inhibitors on blood lipids, verifying possible differences across compounds of this class.
An extensive search of Medline and the Cochrane Library (any date up to December 31, 2010, restricted to randomized clinical trials, published in English) was performed for all trials containing, in any field, the words “sitagliptin,” “vildagliptin,” “saxagliptin,” “alogliptin,” “linagliptin,” and/or “dutogliptin.” Completed but unpublished trials were identified through a search of the ClinicalTrials.gov website, using the same keywords as above. Differences in the endpoint levels and absolute or percent variations of lipids were assessed. A metaregression was performed on the trials specified above to assess the effect of putative moderators on the effect of DPP-4 inhibitors on plasma lipids, considering all drugs together and each one separately.
Although the number of trials of appropriate size and duration was high (n=53), only a small fraction of those (n=17) reported data on endpoint total, high-density lipoprotein, and low-density lipoprotein cholesterol, and triglyceride. The difference-in-means for endpoint versus baseline total cholesterol in patients on DPP-4 inhibitors treatment was significantly higher in comparison with controls, meaning that treatment with DPP-4 inhibitors is associated with a significant reduction in total cholesterol (−0.18 [−0.29; −0.06] mmol/L (−7.0 [−11.2; −2.50] mg/dL); P=0.002).
This meta-analysis suggests a possible beneficial effect of DPP-4 inhibitors on cholesterol, which, although small, could contribute to the reduction of cardiovascular risk.
Keywordscardiovascular risk DPP-4 inhibitors lipid profile meta-analysis
Unable to display preview. Download preview PDF.
- 1.Avogaro A, Giorda C, Maggini M, et al. Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30:1241–1247.PubMedCrossRefGoogle Scholar
- 4.International Diabetes Federation, 2005. Global guideline for type 2 diabetes. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed December 12, 2011.
- 5.Associazione Medici Diabetologi — Società Italiana di Diabetologia. Standard Italiani per la cura del diabete mellito. Available at: http://www.siditalia.it/images/Documenti/2010_linee_guida.pdf. Accessed December 12, 2011.
- 15.Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611–622.PubMedCrossRefGoogle Scholar
- 20.Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther. 2006; 28:1556–1568.PubMedCrossRefGoogle Scholar
- 23.Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397–407.PubMedCrossRefGoogle Scholar
- 37.Monami M, Cremasco F, Lamanna C, et al. Glucagon-like Peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011; [Epub-ahead of print].Google Scholar